AKBA | Complete Akebia Therapeutics Inc. stock news by MarketWatch. 8,047,847 shares traded hands during trading, an increase of 130% from the average session volume of 3,494,822 shares. A number of […] Research Reports. View real-time stock prices and stock quotes for a full financial overview. Washington, D.C. 20549 . Akebia Therapeutics News . November 18, 2020. Akebia Therapeutics Nov 05, 2020, 08:03 ET. The company’s stock price has collected -30.19% of loss in the last five trading sessions. Cambridge, MA 02142, +1 617.871.2098  phone +1 617.871.2099  fax. All news about AKEBIA THERAPEUTICS, INC. 09:55a: AKEBIA THERAPEUTICS: to Participate in Piper Sandler 32nd Annual Virtual Health.. AQ. 11/19: AKEBIA THERAPEUTICS: Ranked 10th Fastest-Growing Company in North America on De.. AQ. © 2020 Akebia Therapeutics. CAMBRIDGE, Mass., Nov. 18, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to … But there was some good news on that front as well. Akebia Therapeutics Ranked 10th Fastest-Growing Company in North America on Deloitte's 2020 Technology Fast 500™ November 16, 2020 Akebia Announces Manuscript Highlighting Global Phase 3 INNO2VATE Program Rationale, Study Design and Baseline Characteristics Published in Peer-Reviewed Medical Journal November 5, 2020 CAMBRIDGE, Mass., May 5, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced positive top-line results from INNO 2 VATE, the first of its two global Phase 3 cardiovascular outcomes programs. Akebia Therapeutics, Inc. (NASDAQ:AKBA) Analysts Are Reducing Their Forecasts For Next Year, Akebia Therapeutics, Inc. (NASDAQ:AKBA) Just Reported And Analysts Have Been Cutting Their Estimates, Akebia Therapeutics Inc (AKBA) Q3 2020 Earnings Call Transcript, Akebia Therapeutics (AKBA) Reports Q3 Loss, Lags Revenue Estimates. Share this article. We are a leader in the renal community – a fully integrated biopharmaceutical company with capabilities ranging from research through commercialization. Follow AKBA. 11/16: AKEBIA THERAPEUTICS: Announces Manuscript Highlighting Global Phase 3 INNO2VATE.. PR. From 2000 to 2006, Dr. Burke served as Senior Vice President of Medical and Regulatory Affairs at Genzyme Corporation, where he worked from 2001 to 2006. November 24, 2020. 11/17: AKEBIA THERAPEUTICS: … Akebia Therapeutics Inc. (NASDAQ:AKBA) went down by -3.24% from its latest closing price compared to the recent 1-year high of $13.71. There are some variant perceptions on Akebia Therapeutics, with the most bullish analyst valuing it at US$10.00 and the most bearish at US$3.00 per share. 08/26 : AKEBIA THERAPEUTICS: Announces First … Akebia Therapeutics Inc. (NASDAQ:AKBA) went down by -10.69% from its latest closing price compared to the recent 1-year high of $13.71. Akebia Therapeutics Since our founding in 2007, Akebia (Nasdaq: AKBA) has been focused on achieving better outcomes for people with kidney disease. The company’s stock price has collected -23.24% of loss in the last five trading sessions. The … Find the latest news headlines from Akebia Therapeutics, Inc. Common Stock (AKBA) at Nasdaq.com. Real time Akebia Therapeutics (AKBA) stock price quote, stock graph, news & analysis. 11/18 : AKEBIA THERAPEUTICS: Ranked 10th … Follow AKBA. Company profile page for Akebia Therapeutics Inc including stock price, company news, press releases, executives, board members, and contact information 09/02: AKEBIA THERAPEUTICS: Reports Inducement Grants Under Nasdaq Listing Rule 5635(c.. PR. Needham rated the Akebia Therapeutics Inc. (NASDAQ: AKBA) stock “a Buy” and gave the company’s common stock a price target of $15. FORM 8-K . News. Needham’s estimates were contained in a research note released on Thursday, November 14, 2019. The company traded as high as $3.18 and last traded at $3.07. Akebia Therapeutics to Participate in Piper Sandler 32nd Annual Virtual Healthcare Conference, Akebia Therapeutics Ranked 10th Fastest-Growing Company in North America on Deloitte's 2020 Technology Fast 500™, Akebia Announces Manuscript Highlighting Global Phase 3 INNO2VATE Program Rationale, Study Design and Baseline Characteristics Published in Peer-Reviewed Medical Journal, Akebia Reports Third Quarter 2020 Financial Results and Recent Business Updates, Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4), Akebia Therapeutics to Report Third Quarter 2020 Financial Results and Discuss Recent Business Highlights, Akebia Presents Results from its PRO₂TECT Global Phase 3 Program of Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients Not on Dialysis During Late-Breaking Session at American Society of Nephrology Kidney Week 2020 Reimagined, Akebia Presents Results from its INNO2VATE Global Phase 3 Program; Demonstrated Efficacy and Cardiovascular Safety of Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients on Dialysis, Akebia to Present Global Phase 3 Vadadustat Data at American Society of Nephrology Kidney Week 2020 Reimagined, Note Regarding Forward Looking Statements. Note: Calculations may not appear exact due to rounding. Recently in News on November 24, 2020, Akebia Therapeutics to Participate in Piper Sandler 32nd Annual Virtual Healthcare Conference. 11/17: AKEBIA THERAPEUTICS: Announces Manuscript Highlighting Global Phase 3 INNO2VATE.. AQ. CURRENT REPORT. Akebia Therapeutics, Inc. The Cambridge, Massachusetts-based company said it had a loss of 42 cents per share. Akebia Therapeutics Ranked 10th Fastest-Growing Company in North America on Deloitte's 2020 Technology Fast 500™ November 16, 2020 Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study design and baseline characteristics of dialysis-dependent patients in the INNO2VATE trials The analysts covering Akebia Therapeutics, Inc. (NASDAQ:AKBA) delivered a dose of negativity to shareholders today, by making a substantial revision to their statutory forecasts for next year.Both revenue and earnings per share (EPS) forecasts went under the knife, suggesting the analysts have soured majorly on the business. News provided by. Akebia Therapeutics to Report Third Quarter 2020 Financial Results and Discuss Recent Business Highlights October 23, 2020 Akebia Presents Results from its PRO₂TECT Global Phase 3 Program of Vadadustat for the Treatment of Anemia due to Chronic Kidney Disease in Adult Patients Not on Dialysis During Late-Breaking Session at American Society of Nephrology Kidney Week 2020 … In Q1, Akebia Therapeutics brought in $88.48 million in sales but lost $59.12 million in earnings.What Is Return On Capital Employed SECURITIES AND EXCHANGE COMMISSION. Akebia Therapeutics Nov 03, 2020, 16:05 ET. Akebia Therapeutics Announces Top-Line Results from its PRO 2 TECT Global Phase 3 Program of Vadadustat for Treatment of Anemia Due to Chronic Kidney Disease in Adult Patients Not on Dialysis September 3, 2020 at 7:00 AM EDT 11/24: AKEBIA THERAPEUTICS: to Participate in Piper Sandler 32nd Annual Virtual Health.. PR. Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. 2 min read (Reuters) - Akebia Therapeutics Inc said on Thursday its experimental drug failed to meet the main safety … Akebia Therapeutics, Inc. is a fully integrated biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease. The good news for vadadustat completely overshadowed Akebia's Q1 financial update. In Q2, Akebia Therapeutics (NASDAQ: AKBA) posted sales of $90.14 million. Share this article. The company’s stock price has collected 0.85% of gains in the last five trading sessions. Currency in USD. Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company focused on the development and commercialization of therapeutics for people living with kidney disease, announced today that its collaboration partner, Japan Tobacco, Inc. (JT), has filed a supplemental New Drug Application (NDA) with Akebia Therapeutics Ranked 10th Fastest-Growing Company in North America on Deloitte's 2020 Technology Fast 500™ PR NewswireWed, Nov. 18 Akebia … 245 First Street, Suite 1400 From 1994 to … Akebia Therapeutics Inc AKBA Morningstar Rating Rating as of Nov 23, 2020. News provided by. Akebia Therapeutics News: This is the News-site for the company Akebia Therapeutics on Markets Insider The two INNO 2 VATE studies evaluated the efficacy and safety … Several other experts on Wall Street have posted such reports regarding the AKBA shares. CAMBRIDGE, Mass., Nov. 3, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to … The Daily Biotech Pulse: Gilead Gets Full Approval For Remdesivir, Akebia's Positive Readout, Foghorn IPO . Shares of Akebia Therapeutics (NASDAQ:AKBA) are plunging today, down 72.3% as of 11:15 a.m. EDT, after the company announced results from a … The analysts covering Akebia Therapeutics, Inc. (NASDAQ:AKBA) delivered a dose of negativity to shareholders today, by making a substantial revision to … Press Release reported 16 hours ago that Akebia Therapeutics to Report Third Quarter 2020 Financial Results and Discuss Recent Business Highlights 11/05: AKEBIA THERAPEUTICS… News provided by. Akebia Therapeutics Nov 18, 2020, 09:37 ET. Akebia Therapeutics Inc. AKBA) on Thursday reported a loss of $60 million in its third quarter. 11/19: AKEBIA THERAPEUTICS: Ranked 10th Fastest-Growing Company in North America on De.. AQ. Akebia Therapeutics: The Drop From The Missed Safety Endpoint Offers A Good Reentry Point . Get the latest Akebia Therapeutics, Inc. (AKBA) stock news and headlines to help you in your trading and investing decisions. Akebia Therapeutics, Inc. (NASDAQ:AKBA)’s stock price shot up 6.6% during mid-day trading on Monday . 3.3001 -0.01 (-0.30%)After hours: 5:17PM EST, Subscribe to Premium to view Fair Value for AKBA, Tip: Try a valid symbol or a specific company name for relevant results, NasdaqGM - NasdaqGM Real Time Price. CAMBRIDGE, Mass., June 18, 2020 /PRNewswire/ -- Akebia Therapeutics ®, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose of bettering the lives of people impacted by kidney disease, today announced David A. Spellman is joining Akebia as its new Senior Vice President, Chief Financial Officer and Treasurer, effective June 29, 2020. Akebia Therapeutics Ranked 10th Fastest-Growing Company in North America on Deloitte's 2020 Technology Fast 500™ November 16, 2020. Find the latest news headlines from Akebia Therapeutics, Inc. Common Stock (AKBA) at Nasdaq.com. Share this article. Akebia Therapeutics Inc. [AKBA] fell into the red zone at the end of the last week, falling into a negative trend and dropping by -16.61. PURSUANT TO SECTION 13 OR 15(D) OF THE SECURITIES EXCHANGE … Akebia Therapeutics, Inc. is down ~75% from its 2020 highs after its oral anemia candidate vadadustat failed to achieve safety non-inferiority versus standard of care in CKD-NDD patients. Statutory earnings fell substantially short of expectations, with revenues of US$60m missing forecasts by 33%. Akebia Therapeutics Inc. (NASDAQ:AKBA) went down by -2.20% from its latest closing price compared to the recent 1-year high of $13.71. In terms of Akebia's commercial performance, net product revenue for Auryxia, ferric citrate increased 14.6% to $34.4 million for the third quarter of … Akebia Therapeutics, Inc. (NASDAQ:AKBA) Just Reported And Analysts Have Been Cutting Their Estimates finance.yahoo.com - November 7 at 8:14 AM: Akebia Therapeutics, Inc. (AKBA) CEO John Butler on Q3 2020 Results - Earnings Call Transcript seekingalpha.com - November 6 at 2:26 PM: Akebia Therapeutics Inc (AKBA) Q3 2020 Earnings Call Transcript Benzinga. Akebia’s privacy procedures do not apply to the owners of a non-Akebia website. Akebia Therapeutics News . 3.39 0.09 (2.73%) Upgrade to Real-Time Afterhours (Closed) Current Report Filing (8-k) September 25 2020 - 08:16AM Edgar (US Regulatory) UNITED STATES. 3.08 0.01 (0.33%) Upgrade to Real-Time Afterhours . The two INNO 2 VATE studies evaluated the efficacy and safety … Below are the latest news stories about Akebia Therapeutics Inc that investors may wish to consider to help them evaluate AKBA as an investment opportunity. Press Release reported on 10/26/20 that Akebia Therapeutics to Report Third Quarter 2020 Financial Results and Discuss Recent Business Highlights Global Phase 3 programme of vadadustat for treatment of anaemia of chronic kidney disease: rationale, study … All news about AKEBIA THERAPEUTICS, INC. 09:38a: AKEBIA THERAPEUTICS: Ranked 10th Fastest-Growing Company in North America on De.. PR. 11/18: AKEBIA THERAPEUTICS: Ranked 10th Fastest-Growing Company in North America on De.. PR. CAMBRIDGE, Mass., Nov. 18, 2020 /PRNewswire/ -- Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to … News. Akebia Therapeutics Announces First Commercial Launch of VAFSEO™ (vadadustat tablets), a New Oral Treatment for Anemia Due to Chronic … Akebia trading halted, news pending 10/22/20 Akebia jumps 8% to $3.55 after INNO2VATE Phase 3 results. Akebia Therapeutics started at outperform with $18 stock price target at Raymond James Aug. 14, 2018 at 8:27 a.m. Akebia reported total revenue of … All rights reserved. Akebia Therapeutics to Participate in Piper Sandler 32nd Annual Virtual Healthcare Conference. Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced that it ranked number 10 on Deloitte's Technology Fast 500™, a ranking of the 500 fastest-growing technology, media, telecommunications, life sciences and energy tech companies in North America, now in its 26th year. Is the Options Market Predicting a Spike in Akebia (AKBA) Stock? You are leaving akebia.com, a website of Akebia Therapeutics, Inc. Akebia does not review or control the content of non-Akebia websites, and this hyperlink does not constitute an endorsement by Akebia of the site’s content. The analysts covering Akebia Therapeutics, Inc. (NASDAQ:AKBA) delivered a dose of negativity to shareholders today, by making a substantial revision to their statutory forecasts for next year.Both revenue and earnings per share (EPS) forecasts went under the knife, suggesting the analysts have soured majorly on the business. Get today's Akebia Ther stock price and latest AKBA news as well as Akebia Ther real-time stock quotes, technical analysis, full financials and more. Press Releases. Prior to joining Akebia, he served as Senior Vice President and Chief Medical Officer of Proteon Therapeutics, Inc., a company developing therapeutics focused on patients with kidney and vascular diseases, from 2006 to 2019. View the latest Akebia Therapeutics Inc. (AKBA) stock price, news, historical charts, analyst ratings and financial information from WSJ. Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to release its financial results for the third quarter ended September 30, 2020, on Thursday, November 5, 2020 before the opening of the financial markets. Most relevant news about AKEBIA THERAPEUTICS, INC. 08:01a: AKEBIA THERAPEUTICS: to Participate in Piper Sandler 32nd Annual Virtual Health.. PR. Akebia Therapeutics, Inc. (NASDAQ:AKBA) Just Reported And Analysts Have Been Cutting Their Estimates finance.yahoo.com - November 7 at 8:14 AM: Akebia Therapeutics, Inc. (AKBA) CEO John Butler on Q3 2020 Results - Earnings Call Transcript seekingalpha.com - November 6 at 2:26 PM: Akebia Therapeutics Inc (AKBA) Q3 2020 Earnings Call Transcript
2020 akebia therapeutics news